ADMA Biologics ADMA Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is ADMA Biologics's other accrued liabilities?
- ADMA Biologics (ADMA) reported other accrued liabilities of $3.35M in Q1 2026.
- How has ADMA Biologics's other accrued liabilities changed year-over-year?
- ADMA Biologics's other accrued liabilities increased by 63.8% year-over-year, from $2.05M to $3.35M.
- What is the long-term trend for ADMA Biologics's other accrued liabilities?
- Over 5 years (2020 to 2025), ADMA Biologics's other accrued liabilities has grown at a 82.3% compound annual growth rate (CAGR), from $207.26K to $4.17M.